New biomarker model aims to reduce unnecessary lung biopsies
NCT ID NCT06074133
First seen Mar 24, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This study is testing a combined biomarker model (CBM) that uses a blood test and CT scan features to better classify lung nodules as benign or cancerous. Researchers will follow 103 adults with intermediate-risk nodules to see if the model can reduce unnecessary invasive procedures and speed up cancer diagnosis. It is an observational pilot study, not a treatment trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY NODULE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, 80045, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
VA Tennessee Valley Healthcare Center
Nashville, Tennessee, 37212, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37203, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a more accurate way to tell if a lung nodule is cancerous, helping patients avoid unnecessary invasive tests.
What could go wrong
This is a small, early pilot study (103 participants) that is only observing outcomes, not testing a treatment. The model may not prove accurate enough in larger trials.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.